PE20050488A1 - Formas de administracion masticables, no comprimidas, dosificadas individualmente - Google Patents

Formas de administracion masticables, no comprimidas, dosificadas individualmente

Info

Publication number
PE20050488A1
PE20050488A1 PE2004001080A PE2004001080A PE20050488A1 PE 20050488 A1 PE20050488 A1 PE 20050488A1 PE 2004001080 A PE2004001080 A PE 2004001080A PE 2004001080 A PE2004001080 A PE 2004001080A PE 20050488 A1 PE20050488 A1 PE 20050488A1
Authority
PE
Peru
Prior art keywords
water
chewable
administration
individually dosed
weight
Prior art date
Application number
PE2004001080A
Other languages
English (en)
Inventor
Gonzalez Nuria Garcia
Vidal Jose Luis Fabregas
Carbonell Antoni Masso
Coll Pere Guiro
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of PE20050488A1 publication Critical patent/PE20050488A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UNA COMPOSICION COMPRENDIDA POR: A) UNA SUSTANCIA FARMACEUTICA DISUELTA EN UN B) MATERIAL MATRIZ QUE COMPRENDE UNA MEZCLA DE: 1) 0,2% EN PESO DE GELATINA, 2) UN AGENTE ESTABILIZADOR, 3) UN ALCOHOL SOLUBLE EN AGUA, Y 4) AGUA. DICHO ESTABILIZADOR SE CARACTERIZA POR SER ESTER DE GLICERINA, PRODUCTO ORIGINADO POR ALCOHOLISIS/ESTERIFICACION DE DICHO ESTER CON POLIETILENGLICOLES Y TENER UN PUNTO DE FUSION ENTRE 42°C A 63°C. EL AGUA NO EXCEDE AL 46% EN PESO DEL TOTAL DE LA COMPOSICION LA CUAL SE PRESENTA COMO GEL MASTICABLE NO COMPRIMIDO ENVASADO EN BLISTER O CAVIDADES
PE2004001080A 2003-11-10 2004-11-05 Formas de administracion masticables, no comprimidas, dosificadas individualmente PE20050488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
PE20050488A1 true PE20050488A1 (es) 2005-08-24

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001080A PE20050488A1 (es) 2003-11-10 2004-11-05 Formas de administracion masticables, no comprimidas, dosificadas individualmente

Country Status (25)

Country Link
US (1) US20070134318A1 (es)
EP (1) EP1682097B1 (es)
JP (1) JP4879021B2 (es)
KR (1) KR20060116821A (es)
CN (1) CN1878542A (es)
AR (1) AR048050A1 (es)
AT (1) ATE492270T1 (es)
AU (1) AU2004290517B2 (es)
BR (1) BRPI0416215A (es)
CA (1) CA2548615A1 (es)
CO (1) CO5690531A2 (es)
DE (1) DE602004030706D1 (es)
EC (1) ECSP066553A (es)
ES (2) ES2235626B1 (es)
IL (1) IL175285A (es)
MY (1) MY143793A (es)
NO (1) NO20062723L (es)
NZ (1) NZ546375A (es)
PE (1) PE20050488A1 (es)
RU (1) RU2369379C2 (es)
TW (1) TW200526266A (es)
UA (1) UA90253C2 (es)
UY (1) UY28586A1 (es)
WO (2) WO2005048975A1 (es)
ZA (1) ZA200602416B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EP2170282A4 (en) * 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2766107A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
KR20220098746A (ko) 2019-11-08 2022-07-12 제논 파마슈티칼스 인크. 우울 장애 치료 방법
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
CZ306277B6 (cs) * 2001-02-14 2016-11-09 Gw Pharma Limited Pumpičkou aktivovaná kapalná sprejová formulace
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
JP2007510690A (ja) 2007-04-26
US20070134318A1 (en) 2007-06-14
IL175285A (en) 2011-04-28
NO20062723L (no) 2006-06-12
UY28586A1 (es) 2005-05-31
WO2005048974A3 (en) 2006-02-23
ES2235626B1 (es) 2006-11-01
UA90253C2 (ru) 2010-04-26
RU2369379C2 (ru) 2009-10-10
CA2548615A1 (en) 2005-06-02
MY143793A (en) 2011-07-15
CN1878542A (zh) 2006-12-13
AU2004290517A1 (en) 2005-06-02
ES2235626A1 (es) 2005-07-01
ZA200602416B (en) 2009-06-24
ECSP066553A (es) 2006-12-20
NZ546375A (en) 2009-11-27
TW200526266A (en) 2005-08-16
ATE492270T1 (de) 2011-01-15
ES2358332T3 (es) 2011-05-09
WO2005048974A2 (en) 2005-06-02
AR048050A1 (es) 2006-03-29
RU2006120087A (ru) 2007-12-27
WO2005048975A1 (en) 2005-06-02
JP4879021B2 (ja) 2012-02-15
CO5690531A2 (es) 2006-10-31
EP1682097B1 (en) 2010-12-22
BRPI0416215A (pt) 2006-12-26
KR20060116821A (ko) 2006-11-15
EP1682097A2 (en) 2006-07-26
IL175285A0 (en) 2006-09-05
DE602004030706D1 (de) 2011-02-03
AU2004290517B2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
PE20050488A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
US6103266A (en) Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
AR048250A1 (es) Productos de pelicula que tienen propiedades de disgregacion controlada
AR045076A1 (es) Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se
AR044131A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
KR880701544A (ko) 이온화 가능한 의약 제제용 용해 시스템
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
UY23356A1 (es) Preparado para la liberacion retardada de sustancias activas, que son apropiadas como sistema terapeutico o para mejorar el crecimiento y el aprovechamiento de los piensos en rumiantes
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
ES2095043T3 (es) Composicion para preparados orales.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
CO4340618A1 (es) Composicion farmaceutica para liberacion controlada
MX171463B (es) Sistema de dosificacion de liberacion sostenida y procedimiento para su preparacion
CO5680461A2 (es) Productos farmaceuticos que comprenden bisfosfonatos
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
ATE353009T1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
PE20050464A1 (es) Formulacion farmaceutica de la sal sodica del telmisartan
AR033688A1 (es) Composicion parenteral reconstituible
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
ES2062697T3 (es) Procedimiento para la incorporacion en pellets de principios activos protegidos contra la degradacion en la panza de los rumiantes.
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed